Skip to content

Clinical effect of Rasayana churna with Kuchala on Rheumatoid Arthritis

A study on the concept of Churna Kriya on Rasayana Churna and its efficacy on Amavata with Kupilu (Strychnous nux-vomica Linn.)

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2011/12/002301
Enrollment
60
Registered
2011-12-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- patients suffering from joint pain and morning stiffness

Interventions

Intervention1: rasayana curna with shuddha kupeelu: Rasayana Churna (combination of Amalaki, Guduchi and Gokshura) without churnakriya along with Shuddha Kupeelu Churna 3.065 g BD with Madhu and Ghrit

Sponsors

IPGTRA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: In addition to the classical symptamatology of Amavata as emphasized in Ayurvedic classics, Presence of any four of the following criteria (based on the revised criteria of American college of Rheumatology : 1987)19. 1. Morning stiffness lasting for more than one hour. 2. Arthritis of three or more joints. 3. Arthritis of hand joints. 4. Symmetrical arthritis. 5. Presence of rheumatoid nodules. 6. Presence of rheumatoid factor. 7. Typical Radiographic changes of Arthritis on PA view of Hand & wrist radiograph that must include erosions & unequivocal decalcification adjacent to involve joints. Criteria 1, 2, 3 & 4 must be present for the duration of six weeks or more.

Exclusion criteria

Exclusion criteria: • Patients having chronic complications like severe crippling deformities • Known case of T.B., Cardiac disease, diabetes, liver disease etc. • Age less than 20 years & more than 50 years

Design outcomes

Primary

MeasureTime frame
Improvement in the signs & symptoms before and after treatment The Assessment Criterion based on the guidelines provided in the Clinical Research Protocol will be considered for the same. Laboratory investigations conducted before and after treatment will also be considered in assessment. t - test will be applied to evaluate clinical significance of the therapy in between the groups. Timepoint: 28 days

Secondary

MeasureTime frame
exacerbation in signs and symptomsTimepoint: 14 days

Countries

India

Contacts

Public ContactDr BJ Patgiri
patgiri06@yahoo.co.in09426947438

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026